When we used the mean of sADO level (694 ng/ml) in our study population as a cutoff to divide the CLL group into two sub-groups: one with sADO < 694 ng/ml and another with sADO ≥ 694 ng/ml, comparison between these two groups regarding demographic data and characteristics showed that the sub-group with sADO ≥ 694 ng/ml has a statistically significant increase in CD38 expression % (P-value < 0.01), sPD-1 (P-value < 0.01), sPD-L1 (P < 0.05). This evidence concerns the gene HOXD13 and B-cell chronic lymphocytic leukemia.